[Ip-health] WHO extends prequalification to new hepaticis C treatments

BEYER, Peter beyerp at who.int
Mon Dec 14 06:22:54 PST 2015

WHO expanded its prequalification programme (http://apps.who.int/prequal/) to now include:

Sofosbuvir tablet, 400 mg
Daclatasvir tablet, 30 mg, 60 mg (preferably scored)
Ledipasvir tablet, 90 mg
Simeprevir capsule, 150 mg
Ribavirin capsule, 200 mg, 400 mg, 600 mg
Sofosbuvir/ Ledipasvir, tablet 400 mg/90 mg
Sofosbuvir/ Daclatasvir, tablet 400 mg/60 mg
Sofosbuvir/ Daclatasvir, tablet 400 mg/30 mg
Ombitasvir/Paritaprevir/Ritonavir, tablet 12.5 mg/75 mg/50 mg
Dasabuvir, tablet 250 mg
Ribavirin syrup, 40 mg/ml (oral)


More information about the Ip-health mailing list